This technology is an assay for detecting select variants of the GCH1 allele and associated genotypes for assessing various psychiatric disorders in patients.
Previous work has shown that patients with schizophrenia have a peripheral deficit in BH4, which is linked to a deficit in the central nervous system. Current methods, however, do not treat psychiatric and neuropsychiatric diseases, such as schizophrenia, by addressing genetic deficiencies in the GCH1 gene and/or in the BH4 system. Additionally, there is currently no useful genetic test for determining subjects that are at-risk for developing schizophrenia and, as a result, treatment approaches have limited success.
This technology is a genetic test for use in assessing psychiatric and neuropsychiatric diseases in patients. This assay determines the presence of select variants of GCH1 alone or in conjunction with low or altered biopterin or BH4. Results from this assay can then be used for the screening, prediction, diagnosis, prognosis, and assessing the treatment response of psychiatric, neuropsychiatric, and neurological disorders. As such, this technology provides an effective assay for diagnosing and determining the treatment for disorders such as schizophrenia, schizoaffective disorder, and bipolar disorder.
IR 2789
Licensing Contact: Ron Katz
